Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Clasificación en acciones #39174
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Precio por acción
$0.378
Última sincronización: 2024-05-24
Capitalización bursátil
$618.41K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio NeuBase Therapeutics, Inc. (NBSE)

Categoría

Historial de desdoblamientos de acciones de NeuBase Therapeutics, Inc. (NBSE)
La acción NeuBase Therapeutics, Inc. (símbolo: NBSE) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 14, 2026.
Una acción NBSE comprada antes de Aug 14, 2026 equivaldría hoy a 0 acciones NBSE.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE